OBJECTIVE: To determine whether clinical trial enrollment by itself is associated with improved outcome. DESIGN: Retrospective cohort study. SETTING: Seattle Children's Hospital from 1997 to 2005. PARTICIPANTS: Data were drawn from 322 patients with newly diagnosed acute lymphoblastic leukemia. Main Exposure Enrollment in a Children's Oncology Group or Children's Cancer Group clinical trial. MAIN OUTCOME MEASURES: (1) Demographic variables associated with trial participation. (2) Event-free survival, which was defined as the time from initial diagnosis to either leukemia recurrence or death from any cause. RESULTS: No outcome advantage was found for participants in a clinical trial compared with nonparticipants. Additionally, there were not demographic factors associated with increased clinical trial participation. CONCLUSIONS: Clinical trial participation does not, by itself, lead to improved outcome for pediatric patients with acute lymphoblastic leukemia in the current era. Discussions about participation in a clinical trial should focus on improvement of future therapy, not the direct benefit of the research participant.
OBJECTIVE: To determine whether clinical trial enrollment by itself is associated with improved outcome. DESIGN: Retrospective cohort study. SETTING: Seattle Children's Hospital from 1997 to 2005. PARTICIPANTS: Data were drawn from 322 patients with newly diagnosed acute lymphoblastic leukemia. Main Exposure Enrollment in a Children's Oncology Group or Children's Cancer Group clinical trial. MAIN OUTCOME MEASURES: (1) Demographic variables associated with trial participation. (2) Event-free survival, which was defined as the time from initial diagnosis to either leukemia recurrence or death from any cause. RESULTS: No outcome advantage was found for participants in a clinical trial compared with nonparticipants. Additionally, there were not demographic factors associated with increased clinical trial participation. CONCLUSIONS: Clinical trial participation does not, by itself, lead to improved outcome for pediatric patients with acute lymphoblastic leukemia in the current era. Discussions about participation in a clinical trial should focus on improvement of future therapy, not the direct benefit of the research participant.
Authors: Henry E Rice; Brian R Englum; Brian C Gulack; Obinna O Adibe; Elizabeth T Tracy; Susan G Kreissman; Jonathan C Routh Journal: Pediatr Blood Cancer Date: 2015-03-21 Impact factor: 3.167
Authors: Heidi V Russell; M Fatih Okcu; Kala Kamdar; Mona D Shah; Eugene Kim; J Michael Swint; Wenyaw Chan; Xianglin L Du; Luisa Franzini; Vivian Ho Journal: BMC Med Inform Decis Mak Date: 2014-10-01 Impact factor: 2.796
Authors: Jason D Pole; Randy Barber; Rose-Émilie Bergeron; Anne Sophie Carret; David Dix; Ketan Kulkarni; Emilie Martineau; Alicia Randall; David Stammers; Caron Strahlendorf; Douglas R Strother; Tony H Truong; Lillian Sung Journal: BMC Cancer Date: 2017-06-05 Impact factor: 4.430
Authors: Daniel Keizman; Keren Rouvinov; Avishay Sella; Maya Gottfried; Natalie Maimon; Jenny J Kim; Mario A Eisenberger; Victoria Sinibaldi; Avivit Peer; Michael A Carducci; Wilmosh Mermershtain; Raya Leibowitz-Amit; Rony Weitzen; Raanan Berger Journal: Cancer Res Treat Date: 2015-03-05 Impact factor: 4.679
Authors: Caron Strahlendorf; Jason D Pole; Randy Barber; David Dix; Ketan Kulkarni; Emilie Martineau; Alicia Randall; David Stammers; Douglas Strother; Tony H Truong; Lillian Sung Journal: Br J Cancer Date: 2018-01-30 Impact factor: 7.640